ArticleScience (New York, N.Y.)2021
Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes.
Article in Science (New York, N.Y.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 132 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
132 citing papers in PubMed, 2 syntheses or guidelines pooled it, 253 citations in OpenAlex.
- Real-Word Effectiveness of Global COVID-19 Vaccines Against SARS-CoV-2 Variants: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2022Pooled it
- Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape.Frontiers in immunology · 2021Pooled it
- Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom.Nature microbiology · 2021Trial
- Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey.Lancet (London, England) · 2021Trial
- Global disparities in COVID-19 vaccine coverage associated with trajectories of SARS-CoV-2 adaptation.BMC infectious diseases · 2026Article
- Epidemiological impacts of nonpharmaceutical interventions are modulated by immunity exposure trade offs.Communications medicine · 2026Article
- Real-time spatiotemporal tracking of infectious outbreaks in confined environments with a host-pathogen agent-based system.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Evolution into chaos - Implications of the trade-off between transmissibility and immune evasion.Infectious Disease Modelling · 2025Article
- Evaluating COVID-19 vaccination policy in Québec (Canada) using a data-driven dynamic transmission model.PLoS computational biology · 2025Article
- The speed of vaccination rollout and the risk of pathogen adaptation.Journal of the Royal Society, Interface · 2025Article
- Pathogen priming alters host transmission potential and predictors of transmissibility in a wild songbird species.mSphere · 2025Article
- Eco-evolutionary dynamics of pathogen immune-escape: deriving a population-level phylodynamic curve.Journal of the Royal Society, Interface · 2025Article
- Epidemic evolutionarily stable strategies within an age-structured host population.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Modeling the SARS-CoV-2 epidemic and the efficacy of different vaccines across different network structures.PloS one · 2025Article
- The evolution of post-infection mortality.Proceedings. Biological sciences · 2024Article
- Adaptive human behaviour modulates the impact of immune life history and vaccination on long-term epidemic dynamics.Proceedings. Biological sciences · 2024Article
- Multispecies interactions and the community context of the evolution of virulence.Proceedings. Biological sciences · 2024Article
- Impact of waning immunity against SARS-CoV-2 severity exacerbated by vaccine hesitancy.PLoS computational biology · 2024Article
- Nanoparticle-Mediated Mucosal Vaccination: Harnessing Nucleic Acids for Immune Enhancement.Current microbiology · 2024Review
- Assessing the impacts of vaccination and viral evolution in contact networks.Scientific reports · 2024Article
72 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Update of
Authors and funding
12 authors at 8 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Given vaccine dose shortages and logistical challenges, various deployment strategies are being proposed to increase population immunity levels to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Two critical issues arise: How timing of delivery of the second dose will affect infection dynamics and how it will affect prospects for the evolution of viral immune escape via a buildup of partially immune individuals. Both hinge on the robustness of the immune response elicited by a single dose as compared with natural and two-dose immunity. Building on an existing immuno-epidemiological model, we find that in the short term, focusing on one dose generally decreases infections, but that longer-term outcomes depend on this relative immune robustness. We then explore three scenarios of selection and find that a one-dose policy may increase the potential for antigenic evolution under certain conditions of partial population immunity. We highlight the critical need to test viral loads and quantify immune responses after one vaccine dose and to ramp up vaccination efforts globally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.